Dec 16 (Reuters) - Janssen Pharmaceutical Companies of Johnson & Johnson:
* JANSSEN - FOLLOWING A PRIORITY REVIEW, HEALTH CANADA APPROVED ERLEADA FOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Dec 16 (Reuters) - Janssen Pharmaceutical Companies of Johnson & Johnson:
* JANSSEN - FOLLOWING A PRIORITY REVIEW, HEALTH CANADA APPROVED ERLEADA FOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER